Can SonoThera’s RIPPLE platform redefine nonviral delivery in oversized genetic payloads?
Can SonoThera’s ultrasound platform reshape gene therapy delivery? Find out how its $125M Series B targets DMD, ADPKD, and XLAS with nonviral precision.
Pharma & Biotech
Pharma & Biotech
ENYO Pharma’s vonafexor reverses kidney decline in Alport syndrome with sustained benefit
Vonafexor reversed kidney decline in Alport syndrome patients. Find out what ENYO Pharma’s Phase 2 results could mean for FXR drugs and kidney care.